<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; TMO</title>
	<atom:link href="http://www.stockbloghub.com/tag/tmo/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Thu, 24 May 2012 23:16:35 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(MDT) MedTech Industry Stock Outlook &#8211; March 2012 &#8211; Zacks Analyst Interviews</title>
		<link>http://www.stockbloghub.com/2012/03/19/mdt-medtech-industry-stock-outlook-march-2012-zacks-analyst-interviews/94611</link>
		<comments>http://www.stockbloghub.com/2012/03/19/mdt-medtech-industry-stock-outlook-march-2012-zacks-analyst-interviews/94611#comments</comments>
		<pubDate>Tue, 20 Mar 2012 02:13:00 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Abiomed Inc]]></category>
		<category><![CDATA[ABMD]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[CNMD]]></category>
		<category><![CDATA[Conmed Corporation]]></category>
		<category><![CDATA[Edwards Lifesciences Corporation]]></category>
		<category><![CDATA[EW]]></category>
		<category><![CDATA[Intuitive Surgical Inc]]></category>
		<category><![CDATA[ISRG]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[PFO]]></category>
		<category><![CDATA[SMA]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[STJ]]></category>
		<category><![CDATA[Stryker Corporation]]></category>
		<category><![CDATA[SYK]]></category>
		<category><![CDATA[Symmetry Medical Inc]]></category>
		<category><![CDATA[Thermo Fisher Scientific Inc]]></category>
		<category><![CDATA[TMO]]></category>
		<category><![CDATA[VAR]]></category>
		<category><![CDATA[Varian Medical Systems Inc]]></category>
		<category><![CDATA[VOLC]]></category>
		<category><![CDATA[Volcano Corporation]]></category>
		<category><![CDATA[WMGI]]></category>
		<category><![CDATA[Wright Medical Group Inc]]></category>
		<category><![CDATA[Zimmer Holdings Inc]]></category>
		<category><![CDATA[ZMH]]></category>
		<category><![CDATA[ZOLL]]></category>
		<category><![CDATA[Zoll Medical Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=94611</guid>
		<description><![CDATA[Last year proved to be challenging for medical technology (“MedTech”) stocks given the exigent economic conditions and the precarious healthcare environment. The performance of incumbent players was hamstrung by several macro issues, including sustained price and procedure volume pressures. The difficult macroeconomic backdrop, pricing headwinds, austerity measures, reimbursement pressure, a still unstable job market and the impact of health care reform continue to weigh on the medical devices industry, exacerbated by Europe&#8217;s sovereign debt plight. With fewer patients going under the knife accompanied by concerns of overuse of devices, companies in the cardiovascular and orthopedic domain continue to grapple with tepid utilization. After having a buoyant first half, the MedTech sector went through a rough patch in the back half of 2011 given the weakened sector fundamentals, sluggish key end-markets ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/03/19/mdt-medtech-industry-stock-outlook-march-2012-zacks-analyst-interviews/94611/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MDT) MedTech Industry Stock Outlook &#8211; March 2012 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2012/03/08/mdt-medtech-industry-stock-outlook-march-2012-industry-outlook/94609</link>
		<comments>http://www.stockbloghub.com/2012/03/08/mdt-medtech-industry-stock-outlook-march-2012-industry-outlook/94609#comments</comments>
		<pubDate>Thu, 08 Mar 2012 19:28:38 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Abiomed Inc]]></category>
		<category><![CDATA[ABMD]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[CNMD]]></category>
		<category><![CDATA[Conmed Corporation]]></category>
		<category><![CDATA[Edwards Lifesciences Corporation]]></category>
		<category><![CDATA[EW]]></category>
		<category><![CDATA[Intuitive Surgical Inc]]></category>
		<category><![CDATA[ISRG]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[PFO]]></category>
		<category><![CDATA[SMA]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[STJ]]></category>
		<category><![CDATA[Stryker Corporation]]></category>
		<category><![CDATA[SYK]]></category>
		<category><![CDATA[Symmetry Medical Inc]]></category>
		<category><![CDATA[Thermo Fisher Scientific Inc]]></category>
		<category><![CDATA[TMO]]></category>
		<category><![CDATA[VAR]]></category>
		<category><![CDATA[Varian Medical Systems Inc]]></category>
		<category><![CDATA[VOLC]]></category>
		<category><![CDATA[Volcano Corporation]]></category>
		<category><![CDATA[WMGI]]></category>
		<category><![CDATA[Wright Medical Group Inc]]></category>
		<category><![CDATA[Zimmer Holdings Inc]]></category>
		<category><![CDATA[ZMH]]></category>
		<category><![CDATA[ZOLL]]></category>
		<category><![CDATA[Zoll Medical Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=94609</guid>
		<description><![CDATA[Last year proved to be challenging for medical technology (“MedTech”) stocks given the exigent economic conditions and the precarious healthcare environment. The performance of incumbent players was hamstrung by several macro issues, including sustained price and procedure volume pressures. The difficult macroeconomic backdrop, pricing headwinds, austerity measures, reimbursement pressure, a still unstable job market and the impact of health care reform continue to weigh on the medical devices industry, exacerbated by Europe&#8217;s sovereign debt plight. With fewer patients going under the knife accompanied by concerns of overuse of devices, companies in the cardiovascular and orthopedic domain continue to grapple with tepid utilization. After having a buoyant first half, the MedTech sector went through a rough patch in the back half of 2011 given the weakened sector fundamentals, sluggish key end-markets ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/03/08/mdt-medtech-industry-stock-outlook-march-2012-industry-outlook/94609/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(STJ) New Year Bets from MedTech</title>
		<link>http://www.stockbloghub.com/2012/01/06/stj-new-year-bets-from-medtech/89062</link>
		<comments>http://www.stockbloghub.com/2012/01/06/stj-new-year-bets-from-medtech/89062#comments</comments>
		<pubDate>Fri, 06 Jan 2012 21:03:25 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[Intuitive Surgical Inc]]></category>
		<category><![CDATA[ISRG]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[STJ]]></category>
		<category><![CDATA[Stryker Corporation]]></category>
		<category><![CDATA[SYK]]></category>
		<category><![CDATA[Thermo Fisher Scientific Inc]]></category>
		<category><![CDATA[TMO]]></category>
		<category><![CDATA[ZOLL]]></category>
		<category><![CDATA[Zoll Medical Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=89062</guid>
		<description><![CDATA[Picking the right stock is never easy, especially in a difficult and volatile market. There are thousands of stocks to choose from and many investors eventually end up boiling the ocean. The U.S. economy continues to be cramped by a spate of headwinds including a still unstable job market, high debt, a soft housing sector and last but surely not the least, the European sovereign debt contagion, which have hit industries across the board. The recent EU summit did not bring out any concrete solution to staunch the debt crisis which began in Greece in 2009. The healthcare sector, traditionally revered as a safe haven for investors and one of the most preferred areas to take cover in the midst of market volatility, has been somewhat proved not immune to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/01/06/stj-new-year-bets-from-medtech/89062/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(TMO) Thermo Fisher Scientific Shares Maintained at Neutral</title>
		<link>http://www.stockbloghub.com/2011/11/30/tmo-thermo-fisher-scientific-shares-maintained-at-neutral/87822</link>
		<comments>http://www.stockbloghub.com/2011/11/30/tmo-thermo-fisher-scientific-shares-maintained-at-neutral/87822#comments</comments>
		<pubDate>Wed, 30 Nov 2011 20:05:19 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Scientific & Technical Instruments]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[Illumina Inc]]></category>
		<category><![CDATA[ILMN]]></category>
		<category><![CDATA[LIFE]]></category>
		<category><![CDATA[Life Technologies Corporation]]></category>
		<category><![CDATA[Thermo Fisher Scientific Inc]]></category>
		<category><![CDATA[TMO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=87822</guid>
		<description><![CDATA[Recently, we reiterated our Neutral recommendation on Thermo Fisher Scientific (TMO) with a target price of $47.00. Thermo Fisher continues to be focused on effectively deploying its cash balance to create value through share buybacks and suitable acquisitions. Significant acquisitions include that of Dionex Corporation and Phadia. The former brings in ion and liquid chromatography portfolio while the latter is a leading player in allergy and autoimmunity diagnostics. Thermo Fisher is actively focused on improving its operating margin. The initiatives include adoption of Practical Process Improvement (PPI) and PPI-Lean projects, continued tight cost control on discretionary spending and infrastructure optimization that includes reduced footprint and expanded low-cost region (LCR) manufacturing (China, Mexico and Eastern Europe). Of Thermo Fisher’s four end markets – Industrial/Applied, Biopharma, Healthcare and Government/Academic – the company ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/11/30/tmo-thermo-fisher-scientific-shares-maintained-at-neutral/87822/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MDT) Medical Technology Industry Stock Outlook &#8211; November 2011 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2011/11/18/mdt-medical-technology-industry-stock-outlook-november-2011-industry-outlook/87069</link>
		<comments>http://www.stockbloghub.com/2011/11/18/mdt-medical-technology-industry-stock-outlook-november-2011-industry-outlook/87069#comments</comments>
		<pubDate>Fri, 18 Nov 2011 18:52:43 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[Abiomed Inc]]></category>
		<category><![CDATA[ABMD]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[BDX]]></category>
		<category><![CDATA[Becton Dickinson Company]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[CNMD]]></category>
		<category><![CDATA[Conmed Corporation]]></category>
		<category><![CDATA[Edwards Lifesciences Corporation]]></category>
		<category><![CDATA[EW]]></category>
		<category><![CDATA[Flaherty & Crumrine Preferred Income Opportunity F]]></category>
		<category><![CDATA[Intuitive Surgical Inc]]></category>
		<category><![CDATA[ISRG]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[PFO]]></category>
		<category><![CDATA[SMA]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[STJ]]></category>
		<category><![CDATA[Stryker Corporation]]></category>
		<category><![CDATA[SYK]]></category>
		<category><![CDATA[Symmetry Medical Inc]]></category>
		<category><![CDATA[Thermo Fisher Scientific Inc]]></category>
		<category><![CDATA[THOR]]></category>
		<category><![CDATA[Thoratec Corporation]]></category>
		<category><![CDATA[TMO]]></category>
		<category><![CDATA[VAR]]></category>
		<category><![CDATA[Varian Medical Systems Inc]]></category>
		<category><![CDATA[VOLC]]></category>
		<category><![CDATA[Volcano Corporation]]></category>
		<category><![CDATA[WMGI]]></category>
		<category><![CDATA[Wright Medical Group Inc]]></category>
		<category><![CDATA[Zimmer Holdings Inc]]></category>
		<category><![CDATA[ZMH]]></category>
		<category><![CDATA[ZOLL]]></category>
		<category><![CDATA[Zoll Medical Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=87069</guid>
		<description><![CDATA[The performance of incumbent players in the MedTech industry continued to be hamstrung by a spate of macro issues (including sustained price and procedure volume pressures) in the September quarter. The prevailing macroeconomic factors, pricing headwinds, austerity measures, reimbursement pressure and the impact of health care reform continues to weigh on the medical devices industry, exacerbated by Europe&#8217;s sovereign debt plight. The beleaguered U.S. implantable defibrillator market continues to bother cardiac devices makers, as reflected by sustained implant volume pressure. On the other hand, companies in the orthopedic domain remain affected by a still choppy reconstructive implant market as they faced sustained pressure across hip, knee and spine businesses in the third quarter (albeit to a lesser extent vis-à-vis the sequentially prior quarter). Although a number of these issues are ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/11/18/mdt-medical-technology-industry-stock-outlook-november-2011-industry-outlook/87069/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MDT) Medical Devices Stock Outlook &#8211; Sept. 2011 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2011/09/08/mdt-medical-devices-stock-outlook-sept-2011-industry-outlook/82743</link>
		<comments>http://www.stockbloghub.com/2011/09/08/mdt-medical-devices-stock-outlook-sept-2011-industry-outlook/82743#comments</comments>
		<pubDate>Thu, 08 Sep 2011 19:53:43 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[Abiomed Inc]]></category>
		<category><![CDATA[ABMD]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[BDX]]></category>
		<category><![CDATA[Becton Dickinson Company]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[CNMD]]></category>
		<category><![CDATA[Conmed Corporation]]></category>
		<category><![CDATA[Edwards Lifesciences Corporation]]></category>
		<category><![CDATA[EW]]></category>
		<category><![CDATA[Flaherty & Crumrine Preferred Income Opportunity F]]></category>
		<category><![CDATA[Intuitive Surgical Inc]]></category>
		<category><![CDATA[ISRG]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[PFO]]></category>
		<category><![CDATA[SMA]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[STJ]]></category>
		<category><![CDATA[Stryker Corporation]]></category>
		<category><![CDATA[SYK]]></category>
		<category><![CDATA[Symmetry Medical Inc]]></category>
		<category><![CDATA[Thermo Fisher Scientific Inc]]></category>
		<category><![CDATA[TMO]]></category>
		<category><![CDATA[VAR]]></category>
		<category><![CDATA[Varian Medical Systems Inc]]></category>
		<category><![CDATA[VOLC]]></category>
		<category><![CDATA[Volcano Corporation]]></category>
		<category><![CDATA[WMGI]]></category>
		<category><![CDATA[Wright Medical Group Inc]]></category>
		<category><![CDATA[Zimmer Holdings Inc]]></category>
		<category><![CDATA[ZMH]]></category>
		<category><![CDATA[ZOLL]]></category>
		<category><![CDATA[Zoll Medical Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=82743</guid>
		<description><![CDATA[June quarter results mostly mirror the preceding quarter as a host of macro headwinds (including price and procedure volume pressures) continued to haunt the MedTech industry and weighed on the performance of the incumbent players. Although a number of these issues are expected to linger over the second-half of 2011, the industry is expected to fare relatively better this year thanks to several tailwinds and growth opportunities. Industry Dynamics The global medical devices industry is fairly large, intensely competitive and highly innovative, with estimated worldwide sales of more than $300 billion in 2011. The U.S. is the largest market, with estimated sales of roughly $95 billion in 2010. The highly-regulated medical devices industry is divided into different segments including Cardiology, Oncology, Neuro, Orthopedic and Aesthetic Devices. The U.S. medical devices ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/08/mdt-medical-devices-stock-outlook-sept-2011-industry-outlook/82743/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BA) Company News for July 28, 2011 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2011/07/28/ba-company-news-for-july-28-2011-corporate-summary/80069</link>
		<comments>http://www.stockbloghub.com/2011/07/28/ba-company-news-for-july-28-2011-corporate-summary/80069#comments</comments>
		<pubDate>Thu, 28 Jul 2011 16:33:58 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Aerospace-Defense - Major Diversified]]></category>
		<category><![CDATA[Industrial Goods]]></category>
		<category><![CDATA[Arcelor Mittal]]></category>
		<category><![CDATA[BA]]></category>
		<category><![CDATA[Boeing Company]]></category>
		<category><![CDATA[IAC-InterActiveCorporation]]></category>
		<category><![CDATA[IACI]]></category>
		<category><![CDATA[JNPR]]></category>
		<category><![CDATA[JPM]]></category>
		<category><![CDATA[JPMorgan Chase & Company]]></category>
		<category><![CDATA[Juniper Networks Inc.]]></category>
		<category><![CDATA[KEYN]]></category>
		<category><![CDATA[Keynote Systems Inc.]]></category>
		<category><![CDATA[Lender Processing Services Inc]]></category>
		<category><![CDATA[LPS]]></category>
		<category><![CDATA[MT]]></category>
		<category><![CDATA[Patriot Coal Corporation]]></category>
		<category><![CDATA[PCX]]></category>
		<category><![CDATA[QCOR]]></category>
		<category><![CDATA[Questcor Pharmaceuticals Inc]]></category>
		<category><![CDATA[Range Resources Corporation]]></category>
		<category><![CDATA[RRC]]></category>
		<category><![CDATA[SBGI]]></category>
		<category><![CDATA[Slair Broadcast Group Inc.]]></category>
		<category><![CDATA[Thermo Fisher Scientific Inc]]></category>
		<category><![CDATA[TMO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=80069</guid>
		<description><![CDATA[•    Boeing (NYSE:BA) reported Q2 EPS of $1.25, beating the Zacks Consensus Estimate of $0.97 per share. Revenues for the quarter rose 6.2% year-over-year to $ 16.5 billion •    Thermo Fisher (NYSE:TMO) reported Q2 EPS of $0.99, ahead of the Zacks Consensus Estimate of $0.98 per share. Revenues for the quarter rose 11.5% year-over-year to $2.90 billion, exceeding the Zacks Consensus Estimate of $2.81 billion •    Arcelor Mittal (NYSE:MT) reported Q2 EPS of $0.99, surpassing the Zacks Consensus Estimate of $0.94 per share. Revenues for the quarter rose 24.7% year-over-year to $25.13 billion, lower than the Zacks Consensus Estimate of $25.3 billion •    Shares of Juniper Networks, Inc. (NYSE:JNPR) plunged 20.89% after the Internet networking equipment provider&#8217;s sales and profit for the second quarter came in below estimates •    Online ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/28/ba-company-news-for-july-28-2011-corporate-summary/80069/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PKI) PerkinElmer Analyst Upgrades Shares to Outperform</title>
		<link>http://www.stockbloghub.com/2011/06/29/pki-perkinelmer-analyst-upgrades-shares-to-outperform/77763</link>
		<comments>http://www.stockbloghub.com/2011/06/29/pki-perkinelmer-analyst-upgrades-shares-to-outperform/77763#comments</comments>
		<pubDate>Wed, 29 Jun 2011 16:41:29 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[PerkinElmer Inc]]></category>
		<category><![CDATA[PKI]]></category>
		<category><![CDATA[Thermo Fisher Scientific Inc]]></category>
		<category><![CDATA[TMO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77763</guid>
		<description><![CDATA[We upgrade our rating on PerkinElmer (PKI) to Outperform based on solid results and benefits accruing from extensive reorganization. First-quarter 2011 earnings per share of 34 cents surpassed the Zacks Consensus Estimate of 30 cents. Revenues from continuing operations came in at $447.9 million, also sailing past the Zacks Consensus Estimate. PerkinElmer is a leader in several life science segments and it has added new related areas as part of its reorganization while divesting unrelated businesses. As a consequence, it has emerged as a higher-growth, higher-margined company focused on human and environmental health. PerkinElmer competes with Thermo Fisher Scientific (TMO) among others. The company views proteomics and genetic screening technologies as its thrust areas in the life sciences segment and it has made investments in high-content screening, proteomics, systems biology ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/29/pki-perkinelmer-analyst-upgrades-shares-to-outperform/77763/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MDT) Medical Devices Stock Outlook &#8211; June 2011 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2011/06/22/mdt-medical-devices-stock-outlook-june-2011-industry-outlook/77179</link>
		<comments>http://www.stockbloghub.com/2011/06/22/mdt-medical-devices-stock-outlook-june-2011-industry-outlook/77179#comments</comments>
		<pubDate>Thu, 23 Jun 2011 01:09:21 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[Abiomed Inc]]></category>
		<category><![CDATA[ABMD]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[BDX]]></category>
		<category><![CDATA[Becton Dickinson Company]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[CNMD]]></category>
		<category><![CDATA[Conmed Corporation]]></category>
		<category><![CDATA[Edwards Lifesciences Corporation]]></category>
		<category><![CDATA[EW]]></category>
		<category><![CDATA[Flaherty & Crumrine Preferred Income Opportunity F]]></category>
		<category><![CDATA[HAE]]></category>
		<category><![CDATA[Haemonetics Corporation]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[PFO]]></category>
		<category><![CDATA[S]]></category>
		<category><![CDATA[SMA]]></category>
		<category><![CDATA[Sprint Nextel Corporation]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[STJ]]></category>
		<category><![CDATA[Stryker Corporation]]></category>
		<category><![CDATA[SYK]]></category>
		<category><![CDATA[Symmetry Medical Inc]]></category>
		<category><![CDATA[Thermo Fisher Scientific Inc]]></category>
		<category><![CDATA[TMO]]></category>
		<category><![CDATA[VAR]]></category>
		<category><![CDATA[Varian Medical Systems Inc]]></category>
		<category><![CDATA[VOLC]]></category>
		<category><![CDATA[Volcano Corporation]]></category>
		<category><![CDATA[WMGI]]></category>
		<category><![CDATA[Wright Medical Group Inc]]></category>
		<category><![CDATA[Zimmer Holdings Inc]]></category>
		<category><![CDATA[ZMH]]></category>
		<category><![CDATA[ZOLL]]></category>
		<category><![CDATA[Zoll Medical Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77179</guid>
		<description><![CDATA[A host of macro headwinds (including price and procedure volume pressure) which hit the MedTech industry last year continued to haunt the sector during the March quarter and encumber growth. Although a number of these issues are expected to linger through the remainder of 2011, the industry is expected to fare relatively better this year thanks to several tailwinds and growth opportunities. Industry Dynamics The global medical devices industry is fairly large, intensely competitive and highly innovative, with estimated worldwide sales of more than $300 billion in 2011. The U.S. is the largest market, with estimated sales of roughly $95 billion in 2010. The medical devices industry is divided into different segments including Cardiology, Oncology, Neuro, Orthopedic and Aesthetic Devices. The U.S. medical devices industry continues to grow at a ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/22/mdt-medical-devices-stock-outlook-june-2011-industry-outlook/77179/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PKI) PerkinElmer Presents Corporate Social Responsibility Report</title>
		<link>http://www.stockbloghub.com/2011/06/22/pki-perkinelmer-presents-corporate-social-responsibility-report/77141</link>
		<comments>http://www.stockbloghub.com/2011/06/22/pki-perkinelmer-presents-corporate-social-responsibility-report/77141#comments</comments>
		<pubDate>Wed, 22 Jun 2011 21:11:24 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[PerkinElmer Inc]]></category>
		<category><![CDATA[PKI]]></category>
		<category><![CDATA[Thermo Fisher Scientific Inc]]></category>
		<category><![CDATA[TMO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77141</guid>
		<description><![CDATA[A global leader in human and environmental health, PerkinElmer (PKI) recently released its Corporate Social Responsibility (“CSR”) Report for 2010. This report provides information on the company’s achievements against its worldwide sustainability target, established in 2009, for environmental health and safety, community activities and product leadership. According to PerkinElmer, it has made solid progress, on account of its over 6,000 employees, to become a more socially responsible entity. In April 2011, the company launched its “For the Better Day” program with the purpose of donating time to voluntary service. PerkinElmer’s CSR objectives concentrate on seamlessly intertwining social and environmental requisites into every aspect of business operation. To achieve these goals, PerkinElmer has recognized three strategic bulwarks each with their own set of targets. With regard to the first pillar, Environment, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/22/pki-perkinelmer-presents-corporate-social-responsibility-report/77141/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(VIVO) FDA OKs Meridian C. Difficile Test</title>
		<link>http://www.stockbloghub.com/2011/05/13/vivo-fda-oks-meridian-c-difficile-test/74020</link>
		<comments>http://www.stockbloghub.com/2011/05/13/vivo-fda-oks-meridian-c-difficile-test/74020#comments</comments>
		<pubDate>Fri, 13 May 2011 20:25:43 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diagnostic Substances]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[BDX]]></category>
		<category><![CDATA[Becton Dickinson Company]]></category>
		<category><![CDATA[Meridian Bioscience Inc.]]></category>
		<category><![CDATA[SI]]></category>
		<category><![CDATA[Siemens AG]]></category>
		<category><![CDATA[Thermo Fisher Scientific Inc]]></category>
		<category><![CDATA[TMO]]></category>
		<category><![CDATA[VIVO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=74020</guid>
		<description><![CDATA[Diagnostic test kit maker Meridian Bioscience (VIVO) has clinched the approval of U.S. Food and Drug Administration (“FDA”) for its new C. difficile (Clostridium difficile) test dubbed Premier C. difficile GDH. The approval of this next-generation test broadens the Cincinnati-based company’s portfolio of C. difficile tests and underscores its sustained commitment to bring out breakthrough products for the detection of C. difficile. Premier GDH has been marketed in Europe since October 2010. C. difficile is a highly drug-resistant bacterium which exists in the environment in spore (or inactive) form and produces a toxin that causes diarrhea and more serious intestinal conditions such as colitis. C. difficile spores are frequently found in hospitals, nursing homes and extended care facilities. Although spores cannot cause infection directly, they transform into the active (or ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/13/vivo-fda-oks-meridian-c-difficile-test/74020/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AFFX) Affymetrix Analyst Initiates Shares at Neutral</title>
		<link>http://www.stockbloghub.com/2011/04/17/affx-affymetrix-analyst-initiates-shares-at-neutral/71708</link>
		<comments>http://www.stockbloghub.com/2011/04/17/affx-affymetrix-analyst-initiates-shares-at-neutral/71708#comments</comments>
		<pubDate>Sun, 17 Apr 2011 18:39:32 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Scientific & Technical Instruments]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[AFFX]]></category>
		<category><![CDATA[Affymetrix Inc]]></category>
		<category><![CDATA[CBMX]]></category>
		<category><![CDATA[CombiMatrix Corporation]]></category>
		<category><![CDATA[Illumina Inc]]></category>
		<category><![CDATA[ILMN]]></category>
		<category><![CDATA[LIFE]]></category>
		<category><![CDATA[Life Technologies Corporation]]></category>
		<category><![CDATA[Sequenom Inc]]></category>
		<category><![CDATA[SQNM]]></category>
		<category><![CDATA[Thermo Fisher Scientific Inc]]></category>
		<category><![CDATA[TMO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=71708</guid>
		<description><![CDATA[We initiate our coverage on genetic products maker Affymetrix (AFFX) with a Neutral recommendation. The company posted respectable results in fourth-quarter fiscal 2010 with earnings beating the Zacks Consensus Estimate while profit surged 42% year over year as lower costs more than offset a decline in sales. California-based Affymetrix is a leading provider of microarray-based products and services to the global research community. Along with Illumina Inc. (ILMN), it is one of the two major providers of microarray technologies primarily used in the field of genetic research. Affymetrix has expertise in gene expression monitoring arrays, which are used to identify correlations between genes, determine their biological functions, and identify patterns that enable more accurate disease classification. It has a dominant position in the gene expression market and enjoys a recurring ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/17/affx-affymetrix-analyst-initiates-shares-at-neutral/71708/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(DGX) Quest Diagnostics Expedites Celera Acquisition</title>
		<link>http://www.stockbloghub.com/2011/04/15/dgx-quest-diagnostics-expedites-celera-acquisition/71625</link>
		<comments>http://www.stockbloghub.com/2011/04/15/dgx-quest-diagnostics-expedites-celera-acquisition/71625#comments</comments>
		<pubDate>Fri, 15 Apr 2011 17:01:06 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Laboratories & Research]]></category>
		<category><![CDATA[Celera Corporation]]></category>
		<category><![CDATA[CRA]]></category>
		<category><![CDATA[DGX]]></category>
		<category><![CDATA[Laboratory Corporation of America Holdings]]></category>
		<category><![CDATA[LH]]></category>
		<category><![CDATA[Quest Diagnostics Inc.]]></category>
		<category><![CDATA[Thermo Fisher Scientific Inc]]></category>
		<category><![CDATA[TMO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=71625</guid>
		<description><![CDATA[Leading diagnostics player, Quest Diagnostics (DGX) took a step forward toward the proposed acquisition of Celera Corporation (CRA). The company recently announced that the waiting period under the HSR Act has expired, though some other conditions are yet to be met. The tender offer to acquire the shares of Celera is supposed to close on April 25, 2011, unless extended further. Last month, Quest decided to acquire Celera for $8 per share, through which the company plans to strengthen its footing in molecular diagnostics discovery and development. Celera’s proprietary genetic tests, pipeline of biomarkers, along with esoteric cardiovascular test, offered by Berkeley HeartLab should drive Quest’s revenues. Celera, with revenues of $128 million in 2010, is expected to add just over 1% to Quest’s 2011 revenue growth. The transaction, to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/15/dgx-quest-diagnostics-expedites-celera-acquisition/71625/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AAPL) Company News For December 13, 2010 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2010/12/13/aapl-company-news-for-december-13-2010-corporate-summary/62163</link>
		<comments>http://www.stockbloghub.com/2010/12/13/aapl-company-news-for-december-13-2010-corporate-summary/62163#comments</comments>
		<pubDate>Tue, 14 Dec 2010 06:47:21 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Personal Computers]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[AAPL]]></category>
		<category><![CDATA[Apple Inc.]]></category>
		<category><![CDATA[BRCM]]></category>
		<category><![CDATA[Broadcom Corporation]]></category>
		<category><![CDATA[CML]]></category>
		<category><![CDATA[Compellent Technologies]]></category>
		<category><![CDATA[DELL]]></category>
		<category><![CDATA[Dell Inc.]]></category>
		<category><![CDATA[Dionex Corporation]]></category>
		<category><![CDATA[DNEX]]></category>
		<category><![CDATA[Goldman Sachs Group]]></category>
		<category><![CDATA[GS]]></category>
		<category><![CDATA[IBM]]></category>
		<category><![CDATA[International Business Machines]]></category>
		<category><![CDATA[JDS Uniphase Corporation]]></category>
		<category><![CDATA[JDSU]]></category>
		<category><![CDATA[MAT]]></category>
		<category><![CDATA[Mattel Inc.]]></category>
		<category><![CDATA[Piper Jaffray Companies]]></category>
		<category><![CDATA[PJC]]></category>
		<category><![CDATA[Thermo Fisher Scientific Inc]]></category>
		<category><![CDATA[TMO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=62163</guid>
		<description><![CDATA[• Thermo Fisher (NYSE:TMO) said it would purchase Dionex (NASDAQ:DNEX), a manufacturer of chemical analysis equipment, for $118.50 per share, or $2.1 billion • According to this weekend&#8217;s Barron&#8217;s, Mattel (NASDAQ:MAT) shares offer good value, with potential for 20% appreciation over the next year • Apple (NASDAQ:AAPL) shares were added by Goldman Sachs&#8217; (NYSE:GS) to its Conviction Buy List, with a target price of $430 • Dell (NASDAQ:DELL) has plans to buy Compellent (NYSE:CML) for $27.75 per share, or $820 million • Goldman Sachs (NYSE:GS) maintained a &#8220;neutral&#8221; rating for IBM (NYSE:IBM) with a target price of $150 • Piper Jaffray (NYSE:PJC) upgraded JDS Uniphase (NASDQ:JDSU) to &#8220;overweight&#8221; and raised the target price from $13 to $17 • Auriga initiated coverage for Broadcom (NASDAQ:BRCM) with a &#8220;buy&#8221; rating and a target price of $55 APPLE INC (AAPL): ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/12/13/aapl-company-news-for-december-13-2010-corporate-summary/62163/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(WAT) Waters Corporation Earnings Slightly Below The Street</title>
		<link>http://www.stockbloghub.com/2010/11/03/wat-waters-corporation-earnings-slightly-below-the-street/56703</link>
		<comments>http://www.stockbloghub.com/2010/11/03/wat-waters-corporation-earnings-slightly-below-the-street/56703#comments</comments>
		<pubDate>Wed, 03 Nov 2010 18:20:57 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Scientific & Technical Instruments]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[A]]></category>
		<category><![CDATA[Agilent Technologies Inc]]></category>
		<category><![CDATA[LIFE]]></category>
		<category><![CDATA[Life Technologies Corporation]]></category>
		<category><![CDATA[Morgan Stanley]]></category>
		<category><![CDATA[MS]]></category>
		<category><![CDATA[Thermo Fisher Scientific Inc]]></category>
		<category><![CDATA[TMO]]></category>
		<category><![CDATA[WAT]]></category>
		<category><![CDATA[Waters Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=56703</guid>
		<description><![CDATA[Waters Corp. (WAT) released its third quarter earnings before the market opened today, reporting earnings from continuing operation of 96 cents, slightly below the Zacks Consensus Estimate of 97 cents.  Earnings in the quarter increased by 21.5% from 79 cents in the third quarter of 2009. Revenue On the top line, WAT outperformed the Zacks Consensus Estimate of $397 million by merely $4 million, reporting total revenue of $401 million.  Total revenue during the quarter increased by 7% year over year as the company delivered solid performance in its pharmaceutical and chemical end markets. Foreign currency translation negatively impacted the company’s sales by 2%. Sales in the quarter were primarily driven by delivery of new instrument systems Incorporatedluding ACQUITY H-Class UPLC and increased demand for the research-focused mass spectrometry products. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/11/03/wat-waters-corporation-earnings-slightly-below-the-street/56703/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(WAT) Waters  Corporation Third Quarter 2010 Earnings Preview</title>
		<link>http://www.stockbloghub.com/2010/10/25/wat-waters-corporation-third-quarter-2010-earnings-preview/56397</link>
		<comments>http://www.stockbloghub.com/2010/10/25/wat-waters-corporation-third-quarter-2010-earnings-preview/56397#comments</comments>
		<pubDate>Tue, 26 Oct 2010 04:48:37 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Scientific & Technical Instruments]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[A]]></category>
		<category><![CDATA[Agilent Technologies Inc]]></category>
		<category><![CDATA[LIFE]]></category>
		<category><![CDATA[Life Technologies Corporation]]></category>
		<category><![CDATA[Thermo Fisher Scientific Inc]]></category>
		<category><![CDATA[TMO]]></category>
		<category><![CDATA[WAT]]></category>
		<category><![CDATA[Waters Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=56397</guid>
		<description><![CDATA[Waters Corp. (WAT) is slated to report its third quarter 2010 earnings on October 26, 2010 before the opening bell. The current Zacks Consensus Estimate for the third quarter is 97 cents per share, representing a year-over-year growth of 4.3%. Waters has surpassed earnings estimates consistently in the last four quarters with a trailing four-quarter average surprise of 3.55%. Second Quarter Recap Waters Corp.’s second quarter 2010 per share from continuing operations was 90 cents, an increase of 25% from 72 cents in the second quarter of 2009. On the top line, Waters outperformed the Zacks Consensus Estimate by merely $3 million, reporting total revenue of $391 million.  Total revenue during the quarter increased by 8% year over year as the company experienced strong demand for its products in key ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/10/25/wat-waters-corporation-third-quarter-2010-earnings-preview/56397/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PKI) PerkinElmer Signs to Aquire Signature Genomic Laboratories</title>
		<link>http://www.stockbloghub.com/2010/04/20/pki-perkinelmer-signs-to-aquire-signature-genomic-laboratories/34388</link>
		<comments>http://www.stockbloghub.com/2010/04/20/pki-perkinelmer-signs-to-aquire-signature-genomic-laboratories/34388#comments</comments>
		<pubDate>Tue, 20 Apr 2010 20:50:15 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[A]]></category>
		<category><![CDATA[Agilent Technologies Inc]]></category>
		<category><![CDATA[PerkinElmer Inc]]></category>
		<category><![CDATA[PKI]]></category>
		<category><![CDATA[Thermo Fisher Scientific Inc]]></category>
		<category><![CDATA[TMO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=34388</guid>
		<description><![CDATA[PerkinElmer Inc. (PKI) announced recently that it has agreed to acquire Signature Genomic Laboratories LLC, a diagnostic genetic testing company. The transaction is expected to close in May 2010. As per the filing with the US Securities and Exchange Commission (SEC), PerkinElmer will acquire the company for $90 million in cash. The deal should enable PerkinElmer strengthen its genetic testing service business and expand its position in early detection of the disease, specifically in the molecular diagnostics market. Furthermore, the deal will bolster PerkinElmer’s position in cancer diagnostics. Through this acquisition, PerkinElmer gains access to strong complementary assets that help in diagnosing disorders that often remain undetected by traditional genetic tests. Furthermore, the broader portfolio will benefit patients, researchers and doctors alike as accurate diagnosis is necessary to treat and ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/20/pki-perkinelmer-signs-to-aquire-signature-genomic-laboratories/34388/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(TMO) Thermo Fisher Scientific Announces Aquisition of Proxeon</title>
		<link>http://www.stockbloghub.com/2010/04/19/tmo-thermo-fisher-scientific-announces-aquisition-of-proxeon/34313</link>
		<comments>http://www.stockbloghub.com/2010/04/19/tmo-thermo-fisher-scientific-announces-aquisition-of-proxeon/34313#comments</comments>
		<pubDate>Mon, 19 Apr 2010 21:48:35 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Scientific & Technical Instruments]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[Thermo Fisher Scientific Inc]]></category>
		<category><![CDATA[TMO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=34313</guid>
		<description><![CDATA[Thermo Fisher Scientific Inc. (TMO) announced that it has acquired Proxeon A/S, an innovative supplier of products for proteomics analysis. Financial terms of the transaction have not been disclosed. Thermo Fisher plans to integrate Proxeon into its Analytical Technologies Segment. The company does not expect the acquisition to have a material impact on its fiscal 2010 results. Proxeon A/S provides a simplified proteomics workflow Incorporatedluding nanoflow liquid chromatography systems, columns, ion sources and bioinformatics software. This allows a robust high-sensitivity liquid chromatography/mass spectrometry (LC/MS) analysis in complex proteomics applications. Proxeon generated sales of roughly $10 million in fiscal 2009. Proxeon’s nanoflow liquid chromatography system, EASY-nLC, is simple and easy to use. The system supports an intuitive graphical user interface and has a remote diagnostics capability. In addition, the compact system ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/19/tmo-thermo-fisher-scientific-announces-aquisition-of-proxeon/34313/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(TMO) Thermo Fisher Scientific Analyst Remains Neutral</title>
		<link>http://www.stockbloghub.com/2010/04/14/tmo-thermo-fisher-scientific-analyst-remains-neutral/33724</link>
		<comments>http://www.stockbloghub.com/2010/04/14/tmo-thermo-fisher-scientific-analyst-remains-neutral/33724#comments</comments>
		<pubDate>Wed, 14 Apr 2010 21:35:37 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Scientific & Technical Instruments]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[Thermo Fisher Scientific Inc]]></category>
		<category><![CDATA[TMO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=33724</guid>
		<description><![CDATA[We have retained our ‘Neutral’ rating on Thermo Fisher Scientific, Inc. (TMO) with a target price of $55 based on a P/E of 16.2 and our fiscal 2010 EPS estimate of $3.39. The company’s results for the fourth quarter and fiscal 2009 were mixed. Thermo Fisher Scientific reported fourth-quarter earnings per share of 91 cents, surpassing the Zacks Consensus Estimate of 88 cents and the year-ago earnings of 87 cents. For fiscal 2009, earnings per share were $3.05, compared to the Zacks Consensus Estimate of $3.02 and $3.13, a year ago. In the fourth quarter, total revenues increased 7% year over year to a record $2.84 billion. Growth was fueled by acquisitions and a favorable foreign currency translation. Analytical Technologies revenues increased 5% year over year to $1.19 billion. Laboratory ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/14/tmo-thermo-fisher-scientific-analyst-remains-neutral/33724/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(TMO) Thermo Fisher Scientific Expands Agreement with Eli Lilly</title>
		<link>http://www.stockbloghub.com/2010/03/29/tmo-thermo-fisher-scientific-expands-agreement-with-eli-lilly/32177</link>
		<comments>http://www.stockbloghub.com/2010/03/29/tmo-thermo-fisher-scientific-expands-agreement-with-eli-lilly/32177#comments</comments>
		<pubDate>Mon, 29 Mar 2010 20:57:23 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Scientific & Technical Instruments]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Thermo Fisher Scientific Inc]]></category>
		<category><![CDATA[TMO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=32177</guid>
		<description><![CDATA[Thermo Fisher Scientific Inc. (TMO) recently expanded its clinical trial materials supply chain relationship agreement with Eli Lilly and Company (LLY). Per the new five-year agreement, Thermo Fisher will take over the responsibility of Lilly’s in-house clinical trial materials manufacturing, packaging and labeling operations at the Lilly Technology Center in Indianapolis. The Fisher Clinical Services segment of Thermo Fisher will handle this transition and expects it to be completed by this summer. Furthermore, the segment will handle the distribution of clinical trial materials for Lilly throughout North America by the end of 2010. The new agreement includes the purchase of Lilly’s clinical trial manufacturing and packaging equipment. This was done to reduce a portion of Lilly’s fixed costs. Eli Lilly has designed a new operating model that speeds the delivery ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/29/tmo-thermo-fisher-scientific-expands-agreement-with-eli-lilly/32177/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(TMO) Thermo Fisher Scientific Acquires Finnzymes</title>
		<link>http://www.stockbloghub.com/2010/03/09/tmo-thermo-fisher-scientific-acquires-finnzymes/30161</link>
		<comments>http://www.stockbloghub.com/2010/03/09/tmo-thermo-fisher-scientific-acquires-finnzymes/30161#comments</comments>
		<pubDate>Tue, 09 Mar 2010 23:06:45 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Scientific & Technical Instruments]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[Thermo Fisher Scientific Inc]]></category>
		<category><![CDATA[TMO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=30161</guid>
		<description><![CDATA[Thermo Fisher Scientific, Inc. (TMO) recently completed the acquisition of Finnzymes. Financial terms of the agreement have not been disclosed. The acquisition is not expected to have any material impact on the company’s financial results in fiscal 2010. Finnzymes is a Finland-based provider of integrated tools for molecular biology analysis Incorporatedluding reagents, instruments, consumables and kits. The company generated revenues of $20 million in fiscal 2009. The Finnzymes acquisition will expand Thermo Fisher’s portfolio of reagents and other consumables for the molecular biology research and diagnostics markets. Finnzymes has expertise in DNA polymerases, which have demonstrated significant increases in the performance of enzymes. This benefits a variety of applications in different fields like genetic testing, basic genomic research, forensics and food testing. Thermo Fisher will add Finnzymes primarily to its ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/09/tmo-thermo-fisher-scientific-acquires-finnzymes/30161/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(TMO) Thermo Fisher Scientific Acquires Ahura</title>
		<link>http://www.stockbloghub.com/2010/03/01/tmo-thermo-fisher-scientific-acquires-ahura/29382</link>
		<comments>http://www.stockbloghub.com/2010/03/01/tmo-thermo-fisher-scientific-acquires-ahura/29382#comments</comments>
		<pubDate>Mon, 01 Mar 2010 23:37:54 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Scientific & Technical Instruments]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[Thermo Fisher Scientific Inc]]></category>
		<category><![CDATA[TMO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=29382</guid>
		<description><![CDATA[Thermo Fisher Scientific, Inc. (TMO) recently completed the acquisition of Ahura Scientific for $145 million in cash plus the potential for an earn-out payment based on the achievement of certain 2010 financial targets. Thermo Fisher has now decided to integrate Ahura into its Analytical Technologies Segment. Ahura Scientific is a leader in handheld Raman and FT-IR (Fourier-transform infrared) spectroscopy instruments that are used globally in the identification of chemicals for safety, security and pharmaceutical applications. The company generated fiscal 2009 revenues of roughly $45 million. The Ahura acquisition will expand Thermo Fisher’s client base that will cater to the company’s top-line growth. Thermo fisher recently reported fourth quarter and full fiscal 2009 results. For the fourth quarter, earnings per share was 91 cents, surpassing the Zacks Consensus Estimate of 88 ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/01/tmo-thermo-fisher-scientific-acquires-ahura/29382/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(TMO) Thermo Fisher Scientific Surpasses Analyst Estimates</title>
		<link>http://www.stockbloghub.com/2010/02/04/tmo-thermo-fisher-scientific-surpasses-analyst-estimates/26965</link>
		<comments>http://www.stockbloghub.com/2010/02/04/tmo-thermo-fisher-scientific-surpasses-analyst-estimates/26965#comments</comments>
		<pubDate>Thu, 04 Feb 2010 22:34:43 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Scientific & Technical Instruments]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[Thermo Fisher Scientific Inc]]></category>
		<category><![CDATA[TMO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=26965</guid>
		<description><![CDATA[Thermo Fisher Scientific, Inc. (TMO) reported fourth quarter and full fiscal 2009 results. For the fourth quarter, earnings per share were 91 cents, surpassing the Zacks Consensus Estimate of 88 cents and the year-ago earnings of 87 cents. For fiscal 2009, earnings per share were $3.05, compared to the Zacks Consensus Estimate of $3.02 and the year-ago earnings of $3.13. Quarterly Results Total revenues in the fourth quarter increased 7% year over year to a record $2.84 billion. Growth was fueled by acquisitions and a favorable foreign currency translation. Analytical Technologies revenues increased 5% year over year to $1.19 billion. Laboratory Products and Services revenues increased 9% year over year to $1.77 billion. The company follows the practice of reporting inter-segment revenues, which were a negative $126.8 million in the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/02/04/tmo-thermo-fisher-scientific-surpasses-analyst-estimates/26965/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(TMO) Thermo Fisher Scientific to Acquire Finnzymes</title>
		<link>http://www.stockbloghub.com/2010/02/04/tmo-thermo-fisher-scientific-to-acquire-finnzymes/27003</link>
		<comments>http://www.stockbloghub.com/2010/02/04/tmo-thermo-fisher-scientific-to-acquire-finnzymes/27003#comments</comments>
		<pubDate>Thu, 04 Feb 2010 22:27:13 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Scientific & Technical Instruments]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[Thermo Fisher Scientific Inc]]></category>
		<category><![CDATA[TMO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=27003</guid>
		<description><![CDATA[Thermo Fisher Scientific Inc. (TMO) has recently signed an agreement to acquire Finnzymes, a provider of integrated tools for molecular biology analysis Incorporatedluding reagents, instruments, consumables and kits. Financial terms of the agreement have not been disclosed. Thermo Fisher expects to complete the acquisition in the first quarter of fiscal 2010. The acquisition is not expected to have any material impact on the company’s financial results in fiscal 2010. The Finnzymes acquisition will expand Thermo Fisher’s portfolio of reagents and other consumables for the molecular biology research and diagnostics markets. Finnzymes has expertise in DNA polymerases, which have demonstrated significant increases in the performance of enzymes. This benefits a variety of applications in different fields such as genetic testing, basic genomic research, forensics and food testing. Finnzymes is a Finland-based ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/02/04/tmo-thermo-fisher-scientific-to-acquire-finnzymes/27003/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(TMO) Thermo Fisher Scientific Analysts Initiate Coverage at Neutral</title>
		<link>http://www.stockbloghub.com/2010/01/08/tmo-thermo-fisher-scientific-analysts-initiate-coverage-at-neutral/24453</link>
		<comments>http://www.stockbloghub.com/2010/01/08/tmo-thermo-fisher-scientific-analysts-initiate-coverage-at-neutral/24453#comments</comments>
		<pubDate>Fri, 08 Jan 2010 21:15:14 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Scientific & Technical Instruments]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[Thermo Fisher Scientific Inc]]></category>
		<category><![CDATA[TMO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=24453</guid>
		<description><![CDATA[We recently initiated coverage on Thermo Fisher Scientific, Inc. (TMO) with a Neutral recommendation. We rate the stock as Neutral with a target price of $50 based on a P/E of 15.0x our fiscal 2010 EPS estimate of $3.33. Thermo Fisher reported third quarter fiscal 2009 earnings per share of 78 cents, surpassing both the Zacks Consensus Estimate and the year-ago earnings of 76 cents. Net sales in the reported quarter declined 2% year over year to roughly $2.5 billion. In terms of business segments: Analytical Technologies revenues declined 6% year over year to $1.0 billion. Laboratory Products and Services revenues increased 1% year over year to $1.6 billion. The company has a practice of reporting inter-segment revenues which have been a negative of $118.8 million for the quarter. Thermo ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/08/tmo-thermo-fisher-scientific-analysts-initiate-coverage-at-neutral/24453/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(TMO) Thermo Fisher Scientific Earns New National Institutes of Health Contract</title>
		<link>http://www.stockbloghub.com/2009/12/17/tmo-thermo-fisher-scientific-earns-new-national-institutes-of-health-contract/23154</link>
		<comments>http://www.stockbloghub.com/2009/12/17/tmo-thermo-fisher-scientific-earns-new-national-institutes-of-health-contract/23154#comments</comments>
		<pubDate>Fri, 18 Dec 2009 01:14:49 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Scientific & Technical Instruments]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[Thermo Fisher Scientific Inc]]></category>
		<category><![CDATA[TMO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=23154</guid>
		<description><![CDATA[Thermo Fisher Scientific Inc. (TMO) recently received a new contract from the consortium of U.S. National Institutes of Health, Centers for Disease Control and Prevention and the Environmental Protection Agency. Thermo Fisher has been selected as the National Children’s Study (NCS) biological and environmental sample repository partner in the contract. Financial terms of the contract have not been disclosed. The NCS study is a popular study in the United States that examines the effects of environmental influences on the health and development of 100,000 children across the nation. Children are examined right before their birth until they become 21 years old. The contract was actually awarded to the Thermo Fisher BioServices segment. Thermo Fisher will maintain a biorepository for storage and disbursement of patient specimens and environmental samples during the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/17/tmo-thermo-fisher-scientific-earns-new-national-institutes-of-health-contract/23154/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(TMO) Thermo Fisher Scientific to Sell $350 Million in Notes</title>
		<link>http://www.stockbloghub.com/2009/11/16/tmo-thermo-fisher-scientific-to-sell-350-million-in-notes/20690</link>
		<comments>http://www.stockbloghub.com/2009/11/16/tmo-thermo-fisher-scientific-to-sell-350-million-in-notes/20690#comments</comments>
		<pubDate>Tue, 17 Nov 2009 01:25:05 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Scientific & Technical Instruments]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[Thermo Fisher Scientific Inc]]></category>
		<category><![CDATA[TMO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=20690</guid>
		<description><![CDATA[Thermo Fisher Scientific Inc. (TMO) decided to sell senior notes for refinancing certain of its outstanding indebtedness. The notes offered are $350 million aggregate principal amount of 2.15% senior notes due 2012 and $400 million aggregate principal amount of 3.25% senior notes due 2014. Issue prices are 99.855% of the principal amount of the 2012 notes and 99.904% of the principal amount of the 2014 notes, respectively. The notes will pay interest on a half-yearly basis and will be offered only to qualified institutional buyers and non-U.S. persons residing outside the United States. The notes are not registered under the U.S. Securities Act, which prevents them to offer to anyone in the United States. The offer is expected to close on Nov 20, 2009. Thermo Fisher will refinance its outstanding ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/16/tmo-thermo-fisher-scientific-to-sell-350-million-in-notes/20690/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(WAT) Waters Corporation Modestly Outperforms</title>
		<link>http://www.stockbloghub.com/2009/10/28/wat-waters-corporation-modestly-outperforms/19043</link>
		<comments>http://www.stockbloghub.com/2009/10/28/wat-waters-corporation-modestly-outperforms/19043#comments</comments>
		<pubDate>Wed, 28 Oct 2009 21:29:45 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Scientific & Technical Instruments]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[A]]></category>
		<category><![CDATA[Agilent Technologies Inc]]></category>
		<category><![CDATA[LIFE]]></category>
		<category><![CDATA[Life Technologies Corporation]]></category>
		<category><![CDATA[Morgan Stanley]]></category>
		<category><![CDATA[MS]]></category>
		<category><![CDATA[Thermo Fisher Scientific Inc]]></category>
		<category><![CDATA[TMO]]></category>
		<category><![CDATA[WAT]]></category>
		<category><![CDATA[Waters Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=19043</guid>
		<description><![CDATA[Waters Corporation (WAT) reported third quarter 2009 revenues of $374 million, a decrease of 3% over that of $386 million in the third quarter of 2008. On a GAAP basis, earnings per diluted share for the third quarter were 79 cents, compared to 71 cents for the third quarter of 2008. This exceeded the Zacks Consensus Estimate of 77 cents per share. Business trends in the third quarter suggested a stabilization of demand by major end markets. Customer interest in new products is encouraging and indicates that research-related spending may benefit its future results. Through the first nine months of 2009, sales for the Company were $1.07 billion, a decrease of 8% in comparison to sales of $1.15 billion in the first nine months of 2008. Foreign currency translation contributed negatively to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/28/wat-waters-corporation-modestly-outperforms/19043/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(TMO) Thermo Fisher Scientific Meets Expectations</title>
		<link>http://www.stockbloghub.com/2009/10/26/tmo-thermo-fisher-scientific-meets-expectations/18690</link>
		<comments>http://www.stockbloghub.com/2009/10/26/tmo-thermo-fisher-scientific-meets-expectations/18690#comments</comments>
		<pubDate>Mon, 26 Oct 2009 22:59:55 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Scientific & Technical Instruments]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[Thermo Fisher Scientific Inc]]></category>
		<category><![CDATA[TMO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=18690</guid>
		<description><![CDATA[Thermo Fisher Scientific Inc. (TMO) today reported financial results for the third quarter of fiscal 2009. Earnings per share came in at 78 cents, exceeding both the Zacks Consensus Estimate and the year-ago earnings of 75 cents. Net sales declined 2% year over year to $2.5 billion. The decline was due to lower Analytical Technologies revenues, partly offset by higher Laboratory Products and Services revenues. Analytical Technologies revenues declined 6% year over year to $1.0 billion. Laboratory Products and Services revenues increased 1% year over year to $1.6 billion. The company has a practice of reporting inter-segment revenues which were a negative $118.8 million for the quarter. Gross margin increased marginally by 10 basis points (bps) year over year to 41.2%. Selling, general and administrative (SG&#38;A) expenses as a percentage ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/26/tmo-thermo-fisher-scientific-meets-expectations/18690/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(TMO) Thermo Fisher Scientific Issues Public Notice on Debenture Conversion</title>
		<link>http://www.stockbloghub.com/2009/10/13/tmo-thermo-fisher-scientific-issues-public-notice-on-debenture-conversion/17482</link>
		<comments>http://www.stockbloghub.com/2009/10/13/tmo-thermo-fisher-scientific-issues-public-notice-on-debenture-conversion/17482#comments</comments>
		<pubDate>Tue, 13 Oct 2009 19:31:46 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Scientific & Technical Instruments]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[A]]></category>
		<category><![CDATA[Agilent Technologies Inc]]></category>
		<category><![CDATA[BEC]]></category>
		<category><![CDATA[Beckman Coulter Inc]]></category>
		<category><![CDATA[Danaher Corporation]]></category>
		<category><![CDATA[DHR]]></category>
		<category><![CDATA[Thermo Fisher Scientific Inc]]></category>
		<category><![CDATA[TMO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=17482</guid>
		<description><![CDATA[Thermo Fisher Scientific Inc. (TMO) recently began the process of issuing public notice to the holders of Floating Rate Convertible Senior Debentures of Apogent Technologies Inc. that are due in 2033, reminding them of their rights to convert the debentures. Thermo Fisher accepted this debt as part of its acquisition of Fisher Scientific International Inc. in 2006 which in turn acquired Apogent Technologies in 2004. As per the indenture/agreement, these debentures have now become convertible as Thermo Fisher’s stock traded above the minimum specified price over the applicable measurement period. The debentures can be converted by the end of this year. Thermo Fisher will use its cash or a combination of cash and its common stock to settle the conversion. Thermo Fisher is a scientific instrument maker and a world ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/13/tmo-thermo-fisher-scientific-issues-public-notice-on-debenture-conversion/17482/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(TMO) Thermo Fisher Scientific Inc Buys BRAHMS</title>
		<link>http://www.stockbloghub.com/2009/09/10/tmo-thermo-fisher-scientific-inc-buys-brahms/14834</link>
		<comments>http://www.stockbloghub.com/2009/09/10/tmo-thermo-fisher-scientific-inc-buys-brahms/14834#comments</comments>
		<pubDate>Thu, 10 Sep 2009 22:06:12 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Scientific & Technical Instruments]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[Danaher Corp.]]></category>
		<category><![CDATA[DHR]]></category>
		<category><![CDATA[Thermo Fisher Scientific Inc]]></category>
		<category><![CDATA[TMO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=14834</guid>
		<description><![CDATA[Thermo Fisher Scientific Inc. (TMO) recently agreed to acquire B.R.A.H.M.S. AG for 330 million Euros or about $470 million. B.R.A.H.M.S. is a leading provider of specialty in-vitro diagnostic tests based on its patented biomarkers for sepsis, cardiovascular and pulmonary diseases, as well as intensive care treatments and prenatal screening. The company is based outside of Berlin in Hennigsdorf, Germany, and has sales offices in Europe and the U.S. With nearly 400 employees serving customers in 65 countries around the world, B.R.A.H.M.S. generated 2008 sales of 75 million Euros or about $105 million. The transaction is expected to be accretive to earnings in 2010. The news comes a day after diversified US manufacturer Danaher Corp. (DHR) said it would buy two scientific instrument businesses for a total of $1.1 billion. B.R.A.H.M.S. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/10/tmo-thermo-fisher-scientific-inc-buys-brahms/14834/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

